NCT03149822View on ClinicalTrials.gov

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

December 14, 2022

Study Completion Date

February 16, 2024

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Pharmaceutical form: tablets Route of administration: oral

DRUG

Pembrolizumab

Pharmaceutical form: solution Route of administration: injection

Trial Locations (5)

80045

University of Colorado Denver, Aurora

80124

UCHealth Lone Tree Medical Center, Lone Tree

80129

Highlands Ranch Hospital, Highlands Ranch

80528

Poudre Valley Hospital, Fort Collins

80909

Memorial Hospital Central, Colorado Springs

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter